Letter: FGF-23 as a Potential Prognostic Biomarker in Peripheral Artery Disease

Abstract

Get full access to this article

View all access options for this article.

References

Zierfuss

Bojic

Schernthaner

Höbaus

FGF-23 and long-term outcome in peripheral artery disease. Angiology. 2026;77:630-666.

Latic

Lari

Sun

, et al. Deletion of cardiac fibroblast growth factor-23 beneficially impacts myocardial energy metabolism in left ventricular hypertrophy. NPJ Metab Health Dis. 2025;3:42.

Hao

, et al. FGF23 promotes myocardial fibrosis in mice through activation of β-catenin. Oncotarget. 2016;7:64649-64664.

Silswal

Touchberry

Daniel

, et al. FGF23 directly impairs endothelium-dependent vasorelaxation by increasing superoxide levels and reducing nitric oxide bioavailability. Am J Physiol Endocrinol Metab. 2014;307:E426-E436.

Kuro-O

The Klotho proteins in health and disease. Nat Rev Nephrol. 2019;15:27-44.

Biscetti

Giovannini

Iezzi

, et al. Association of Klotho and FGF23 with cardiovascular outcomes in diabetic older adults with chronic limb-threatening ischemia: a prospective study. Geroscience. 2025;47:4921-4934.